Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 8,271 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Age Clear all
Not listed Phase 4 Interventional

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

NCT01670162
View directory record Official record
Conditions
Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Nov 8, 2026, 10:26 AM EST
Completed Phase 2 Interventional Results available

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

NCT03292588
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Nov 8, 2026, 10:26 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement

NCT04570579
View directory record Official record
Conditions
Cataract, Cataract Senile, Presbyopia
Interventions
Vivity Extended Depth of Focus Intraocular Lens
Device
Lead sponsor
Alanna Nattis, DO
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Babylon, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NCT02014896
View directory record Official record
Conditions
Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke of Basilar Artery, Cardioembolic Stroke
Interventions
Biomarker blood draw
Other
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Sacramento, California • San Francisco, California • Detroit, Michigan + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 8, 2026, 10:26 AM EST
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 8, 2026, 10:26 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Early Detection of Breast Cancer

NCT06043661
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
Datar Cancer Genetics Inc
Industry
Eligibility
40 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Oklahoma Native American Women's Osteoporosis Screening Study

NCT01939470
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Oklahoma State University
Other
Eligibility
50 Years and older · Female only
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 8, 2026, 10:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Feasibility of Rice Bran Supplementation in Children

NCT02557373
View directory record Official record
Conditions
Dietary Rice Bran Supplementation
Interventions
Vitamin A, Rice Bran + Vitamin A
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
4 Months to 10 Months
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Nov 8, 2026, 10:26 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

NCT00973362
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay, FDA-Approved HPV DNA Test
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
12,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
17
States / cities
Jonesboro, Arkansas • Canoga Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Nov 8, 2026, 10:26 AM EST
Completed Phase 2 Interventional

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

NCT00684827
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Encinitas, California • Los Angeles, California • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Out-of-hospital Cardiac Arrest (OHCA) Biomarkers

NCT03112486
View directory record Official record
Conditions
Neurological Outcome, Cardiac Arrest, Out-Of-Hospital Cardiac Arrest, Brain Anoxia Ischemia, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Cardiac Arrest With Successful Resuscitation, Cardiac Arrest, Out-Of-Hospital, Brain Injuries
Interventions
blood draw
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Nov 8, 2026, 10:26 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

NCT04508088
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease
Interventions
Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 8, 2026, 10:26 AM EST
Completed Phase 4 Interventional Results available

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

NCT00105586
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational

Adipose Tissue and Serum Inflammation in GH Deficiency

NCT03500913
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth Hormone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Nov 8, 2026, 10:26 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT06556368
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

NCT01146990
View directory record Official record
Conditions
Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
Interventions
ASQ-3, Bayley III, Neurologic exam
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
22 Months to 25 Months
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational

A Retrospective Chart Abstraction to Investigate the Prevalence of Chronic Sialorrhea, and the Real-world Use of incobotulinumtoxinA Injections in Male and Female Participants Aged 18 Years and Older With Chronic Sialorrhea

NCT07881497
View directory record Official record
Conditions
Sialorrhea
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Olney, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 8, 2026, 10:26 AM EST
Enrolling by invitation No phase listed Observational

A Review of Precice Intramedullary Limb Lengthening (IMLL) System for Limb Lengthening Procedures in Children.

NCT06714110
View directory record Official record
Conditions
Limb Length Discrepancy
Interventions
Intramedullary Limb Lengthening Device, External Fixator Limb Lengthening Device
Device
Lead sponsor
NuVasive
Industry
Eligibility
0 Months to 12 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Nov 8, 2026, 10:26 AM EST
Completed Not applicable Interventional

Food Resource Equity and Sustainability for Health

NCT03251950
View directory record Official record
Conditions
BMI, Blood Pressure
Interventions
healthy eating and gardening
Behavioral
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
3 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 8, 2026, 10:26 AM EST
Completed No phase listed Observational

AMD Phenotype and Genotype Study

NCT01778491
View directory record Official record
Conditions
Age-Related Macular Degeneration, AMD
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
60 Years to 90 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Nov 8, 2026, 10:26 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

NCT01000974
View directory record Official record
Conditions
Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
63
States / cities
Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Nov 8, 2026, 10:26 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Trial of a Network Intervention for Youth After Incarceration

NCT03556618
View directory record Official record
Conditions
Youth Incarceration, Health Care Utilization
Interventions
Whole Person Care (WPC) Reentry Program - Pre & Post Release services
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 24 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Nov 8, 2026, 10:26 AM EST
Terminated Phase 3 Interventional Results available

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757610
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 8, 2026, 10:26 AM EST
Recruiting No phase listed Observational

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

NCT07645391
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 8, 2026, 10:26 AM EST